Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

20121,876 citationsJournal Article

Authors

Jonathan A. Ledermann · UCL Biomedical Research Centre

Philipp Harter · Kliniken Essen-Mitte

Charlie Gourley · Edinburgh Cancer Research

Michael Friedländer · Prince of Wales Hospital

Ignace Vergote · KU Leuven

Gordon Rustin · Mount Vernon Hospital

Clare L. Scott ·

Abstract

Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit. The toxicity profile of olaparib in this population was consistent with that in previous studies. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT00753545.).

Topics & Keywords

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 15, pp. 1382-1392

DOI: 10.1056/nejmoa1105535

Field-Weighted Citation Impact: 50.57